Warren Foust of STAAR Surgical (STAA) receives 20,787 RSUs as interim Co-CEO

Rhea-AI Filing Summary

STAAR Surgical granted restricted stock units to Interim Co-CEO and President & COO Warren Foust. On February 2, 2026, he received 20,787 RSUs, each representing one share of common stock upon vesting at a price of $0 per unit.

The RSUs will vest as to 100% of the shares on August 1, 2026, assuming the vesting conditions are met. Following this grant, Foust beneficially owns 20,787 derivative securities directly in the form of these RSUs.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Foust Warren

(Last) (First) (Middle)

25510 COMMERCENTRE DRIVE

(Street)

LAKE FOREST CA 92630

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STAAR SURGICAL CO [ STAA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim Co-CEO and Pres. & COO

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(1)	02/02/2026		A		20,787		(2)	(2)	Common Stock	20,787	$0	20,787	D

Explanation of Responses:

1. Each restricted stock unit (RSU) represents the right to receive one share of the Corporation's common stock upon vesting.

2. Award of RSUs granted to the Reporting Person on February 2, 2026. These RSUs will vest as to 100% of the shares subject thereto on August 1, 2026.

Remarks:

This Form 4 reflects the RSUs granted to Mr. Foust in connection with his appointment as Interim Co-Chief Executive Officer on February 2, 2026.

	/s/ Nathaniel Sisitsky as attorney-in-fact for Warren Foust	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did STAAR Surgical (STAA) report for Warren Foust?

STAAR Surgical reported a grant of 20,787 restricted stock units to Interim Co-CEO and President & COO Warren Foust. The award was made on February 2, 2026 and is structured as equity-based compensation rather than a cash transaction.

How many restricted stock units did STAAR Surgical (STAA) grant to its interim Co-CEO?

STAAR Surgical granted 20,787 restricted stock units to Interim Co-CEO Warren Foust. Each RSU represents the right to receive one share of common stock upon vesting, giving him potential future ownership aligned with shareholder interests.

When do Warren Foust’s STAAR Surgical (STAA) RSUs vest?

The 20,787 restricted stock units granted to Warren Foust will vest 100% on August 1, 2026. Vesting must occur before the RSUs convert into shares of STAAR Surgical common stock deliverable to him.

What price did Warren Foust pay for his STAAR Surgical (STAA) RSU grant?

The RSU grant to Warren Foust has a reported price of $0 per unit. This reflects that restricted stock units are typically granted as compensation and do not require a cash payment at the time of grant by the executive.

How many STAAR Surgical (STAA) derivative securities does Warren Foust now hold?

Following this transaction, Warren Foust beneficially owns 20,787 derivative securities in the form of restricted stock units. These units are held directly and may convert into an equal number of common shares upon vesting.

Why did STAAR Surgical (STAA) grant RSUs to Warren Foust?

The RSU grant was made in connection with Warren Foust’s appointment as Interim Co-Chief Executive Officer. This equity award aligns his compensation with company performance by tying future share delivery to continued service through the vesting date.